LaborMed, 47% higher sales to 12.8m euros

LaborMed Pharma, the Romanian drugmaker, in the first half of this year logged sales revolving around 12.8 million euros, up 47% from the corresponding period of last year, in line with Cegedim data quoted by the company. “Sales advanced amid the launch of new products, market growth along the segments LaborMed Pharma operates on, as well as investments in sales and promotion force training,” stated Marcian Gavrilescu, general manager of LaborMed Pharma Trading. He specified sales derived during the period were based on the same portfolio structure, with the structure set to change in the future due to newly registered drugs, designed for the central nervous system and diabetes. The main therapeutic field LabourMed specialises in is the cardiovascular drug segment. The company currently holds 2% of the domestic drug market and has around 70 drugs in its portfolio. LaborMed also exports its products. For 2006, the company has budgeted turnover worth over 30 million euros, 50% higher compared to the previous year. The company last year registered sales worth 19.5 million euros, placing it fifth among Romania’s biggest drug producers. The most important players on the Romanian pharmaceutical market are GlaxoSmithKline, Hoffmann La Roche, Novartis and Sanofi-Aventis.